Laurus Labs rebound after poor Q3FY22 results as CDMO, API & Formulation segments witness growth but API segment continues to face headwinds | Q4 FY22 Result & Earning Call Highlights
Laurus Labs rebound after poor Q3FY22 results as CDMO, API & Formulation segments witness growth but API segment continues to face headwinds | Q4 FY22 Result & Earning Call Highlights
Laurus Labs rebound after poor Q3FY22 results as CDMO, API & Formulation segments witness growth but API segment continues to face headwinds | Q4 FY22 Result & Earning Call Highlights